Bumex (oral/injection) Pregnancy Warnings
Bumetanide has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity. A dose-related decrease in litter size and an increase in resorption rate were noted in rabbits at doses between 3.4 and 10 times the maximum recommended therapeutic human dose (on a per kg basis). There are no data from human pregnancy studies. Bumetanide should only be given during pregnancy when benefit outweighs risk.
See references
Bumex (oral/injection) Breastfeeding Warnings
There are no data on the excretion of bumetanide into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
See references